Unknown

Dataset Information

0

Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis.


ABSTRACT: Clofazimine and high-dose rifapentine have each separately been associated with treatment-shortening activity when incorporated into tuberculosis (TB) treatment regimens. We hypothesized that both modifications, i.e., the addition of clofazimine and the replacement of rifampin with high-dose rifapentine, in the first-line regimen for drug-susceptible TB would significantly shorten the duration of treatment necessary for cure. We tested this hypothesis in a well-established BALB/c mouse model of TB chemotherapy and also in a C3HeB/FeJ mouse model in which mice can develop caseous necrotic lesions, an environment where rifapentine and clofazimine may individually be less effective. In both mouse models, replacing rifampin with high-dose rifapentine and adding clofazimine in the first-line regimen resulted in greater bactericidal and sterilizing activity than either modification alone, suggesting that a rifapentine- and clofazimine-containing regimen may have the potential to significantly shorten the treatment duration for drug-susceptible TB. These data provide preclinical evidence supporting the evaluation of regimens combining high-dose rifapentine and clofazimine in clinical trials.

SUBMITTER: Saini V 

PROVIDER: S-EPMC6535519 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis.

Saini Vikram V   Ammerman Nicole C NC   Chang Yong Seok YS   Tasneen Rokeya R   Chaisson Richard E RE   Jain Sanjay S   Nuermberger Eric E   Grosset Jacques H JH  

Antimicrobial agents and chemotherapy 20190524 6


Clofazimine and high-dose rifapentine have each separately been associated with treatment-shortening activity when incorporated into tuberculosis (TB) treatment regimens. We hypothesized that both modifications, i.e., the addition of clofazimine and the replacement of rifampin with high-dose rifapentine, in the first-line regimen for drug-susceptible TB would significantly shorten the duration of treatment necessary for cure. We tested this hypothesis in a well-established BALB/c mouse model of  ...[more]

Similar Datasets

| S-EPMC3421552 | biostudies-literature
| S-EPMC6021677 | biostudies-literature
| S-EPMC4233406 | biostudies-literature
| S-EPMC2718441 | biostudies-other
| S-EPMC4311815 | biostudies-other
| S-EPMC7307310 | biostudies-literature
| S-EPMC6624831 | biostudies-literature
| S-EPMC4861335 | biostudies-literature
| S-EPMC8097486 | biostudies-literature
| S-EPMC11326837 | biostudies-literature